This study explores the potential of Lacticaseibacillus rhamnosus LRa05 as a novel probiotic treatment for Candidal vaginitis. Isolated from fecal samples, LRa05 demonstrates superior antagonistic activity against Candida albicans, surpassing commercially available strains LGG, RC-14, and GR-1.

Chronic kidney disease (CKD) is a significant health concern characterized by the accumulation of uremic toxins in the blood, which are difficult to remove via dialysis. This study presents a novel probiotic composition, comprising Lacticaseibacillus rhamnosus LRa66 and Bifidobacterium bifidum BBi32, designed to regulate serum uremic toxins and alleviate CKD symptoms.

This study introduces a novel probiotic agent with significant anti-allergic properties. The agent comprises two strains: Bifidobacterium animalis subsp. lactis BLa36 and Lacticaseibacillus casei LC89.

This study presents the discovery and application of Lacticaseibacillus rhamnosus LRa66, a novel probiotic strain exhibiting significant capabilities of blood glucose and lipid reduction. Isolated from human breast milk, LRa66 demonstrates superior tolerance to gastric acid, intestinal fluid, and bile salts.

The study investigates the properties and applications of a novel strain of Lacticaseibacillus casei LC15 with significant immune-modulating and antimicrobial activities.

The present study introduces a composite probiotic blend comprising Bifidobacterium animalis subsp. lactis BLa36 and Bifidobacterium breve BBr60. This blend demonstrates synergistic effects in stabilizing mood by balancing neurotransmitters, reducing stress responses, and improving behavioral symptoms.